Navigation Links
Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
Date:3/7/2012

BURLINGAME, Calif. and LONGNAN CITY, China, March 6, 2012  /PRNewswire/ -- Apexigen, Inc., a privately held biopharmaceutical company, and Gansu Duyiwei Biological Pharmaceutical Co., Ltd. (GDBP), which is listed on the Shenzhen stock exchange, today announced that they entered into a collaboration to grant an exclusive license to GDBP to develop and commercialize APX004 in China.   APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases.  Under this agreement, GDBP will have an exclusive license and sole responsibility to research, develop and commercialize APX004 in China.  Apexigen retains all rights to APX004 outside of China and will collaborate with GDBP to advance the development program.  Under the terms of the agreement, Apexigen will receive an upfront payment, milestone payments on the successful achievement of regulatory milestones, and a royalty.  Financial terms were not disclosed.

"The pharmaceutical market in China today is very dynamic.  We are pleased to be partnering with Gansu Duyiwei for the development and commercialization of APX004 in this vibrant market.  We're looking forward to a productive partnership," said Dr. Xiaodong Yang, Apexigen's President and CEO.  

"During the last century, people often said that the century to come will be the biological science century.  The report of a survey from an American marketing research institute, Alt Assets, shows that the prospects for the global biotechnology industry are very promising. The sales revenue for products of the bio-economy, that is, products based on biological science and biotechnology, will exceed 15 trillion US Dollars in 30 years and the bio-economy will outrun the information economy and become the most powerful economic force in the world. The cooperation between Duyiwei and Apexigen will become a developmental milestone for Du
'/>"/>

SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
2. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
3. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
4. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
5. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
6. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
7. Sundia Shortens CRO Shipment Delivery Time with Express Customs Clearance in Shanghai
8. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
9. Pharma and Biotech Leaders to Converge in Shanghai
10. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
11. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, Inc. ... treatments for urological and related conditions, announced today that ... private placement convertible note financing, raising a total of ... totaling $3.175 million. Josh Disbrow ... this private placement are intended to be used to ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... Associates has announced the development of the Core Communications Program, ... investors, collaborators, and customers. , ... ... http://www.mainsgate.com [Mains Associates] has announced the availability of ...
... electronic properties, few layer graphene, or FLG, has emerged ... devices that incorporate the quantum effects that emerge at ... Pennsylvania have demonstrated a new method by which FLG ... thermally activated nanoparticles, a technique that results in atomically ...
... (Nasdaq: ONXX ) today announced that it ... Pharmaceuticals Conference on,Thursday, August 7, at 3:05 p.m. ... of the presentation on our website at:, http://www.onyx-pharm.com/wt/page/event_calendar ... on 15 minutes early in order to,register and ...
Cached Biology Technology:Bay-Area Company Gives Science-Based Startups a Voice 2Penn scientists carve functional nanoribbons using super-heated, nano-sized particles of iron 2
(Date:9/2/2015)... FELTON, California , September 2, 2015 /PRNewswire/ ... with the security purpose implied in a system ... hand geometry, voice, signature, iris, vein, DNA and ... crimes has forced to develop such system which ... by username, password, PIN, Patterns and tokens are ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... GSA BULLETIN articles posted online ahead of print ... Valley Antarctica; Death Valley, California, USA; Esan Volcanic Complex, ... include how melting affects granite emplacement; "how do you ... the evolution of Death Valley; and the risk of ...
... Biofuels developed from plant biomass and purpose-grown crops can ... new report says, but only through the wise allocation ... throughout the state. That,s the conclusion of "California ... the California Council on Science and Technology (CCST) co-authored ...
... a significant improvement in cardiac function after being treated with ... research, led by a team of scientists at the Buck ... tissues, providing functional insights and possible benefits for a drug ... as much as 14 percent. There are implications for human ...
Cached Biology News:7 new GSA Bulletin articles posted online ahead of print 27 new GSA Bulletin articles posted online ahead of print 37 new GSA Bulletin articles posted online ahead of print 47 new GSA Bulletin articles posted online ahead of print 57 new GSA Bulletin articles posted online ahead of print 67 new GSA Bulletin articles posted online ahead of print 7Biofuels will play integral role in California's energy future, says new EBI study 2Biofuels will play integral role in California's energy future, says new EBI study 3Lifespan-extending drug given late in life reverses age-related heart disease in mice 2
... Clone/PAD: ZMD.473. Immunogen: Synthetic ... of the mouse junctophilin-2. Specificity: ... Reactivity: Mouse (positive controls: mouse skeletal ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
TGF-beta 2 MAb (Clone 8607)...
UCP1/2/3 (FL-307)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products: